87 related articles for article (PubMed ID: 26178438)
21. Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.
Beumer JH; Joseph E; Egorin MJ; Covey JM; Eiseman JL
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):147-55. PubMed ID: 16364698
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma.
Frazier SA; McKemie DS; Guerrero TA; Skorupski KA; Rodriguez CO
Am J Vet Res; 2011 Feb; 72(2):263-70. PubMed ID: 21281203
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs.
Intile JL; Rassnick KM; Bailey DB; Al-Sarraf R; Chretin JD; Balkman CE; Flory AB; Kiselow MA; Wakshlag JJ
Vet Comp Oncol; 2009 Mar; 7(1):69-77. PubMed ID: 19222832
[TBL] [Abstract][Full Text] [Related]
25. Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study
Athanasiadi I; Geigy C; Hilger RA; Meier V; Rohrer Bley C
Vet Comp Oncol; 2017 Mar; 15(1):94-104. PubMed ID: 25689225
[TBL] [Abstract][Full Text] [Related]
26. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
27. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.
Scott SA; Lakshimikuttysamma A; Sheridan DP; Sanche SE; Geyer CR; DeCoteau JF
Exp Hematol; 2007 Feb; 35(2):263-73. PubMed ID: 17258075
[TBL] [Abstract][Full Text] [Related]
28. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology.
Marquez VE; Barchi JJ; Kelley JA; Rao KV; Agbaria R; Ben-Kasus T; Cheng JC; Yoo CB; Jones PA
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):305-18. PubMed ID: 16247946
[TBL] [Abstract][Full Text] [Related]
29. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Heading KL; Brockley LK; Bennett PF
Aust Vet J; 2011 Apr; 89(4):109-16. PubMed ID: 21418164
[TBL] [Abstract][Full Text] [Related]
30. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
Thamm DH; MacEwen EG; Phillips BS; Hershey AE; Burgess KM; Pettit GR; Vail DM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):251-5. PubMed ID: 11935218
[TBL] [Abstract][Full Text] [Related]
31. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
32. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs.
McEntee MC; Rassnick KM; Lewis LD; Zgola MM; Beaulieu BB; Balkman CE; Page RL
Am J Vet Res; 2006 Jun; 67(6):1057-62. PubMed ID: 16740102
[TBL] [Abstract][Full Text] [Related]
34. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
[TBL] [Abstract][Full Text] [Related]
36. Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
Allstadt Frazier S; McKemie DS; Guerrero TA; LaChapelle H; Skorupski KA; Kass PH; Rodriguez CO
Vet Comp Oncol; 2014 Mar; 12(1):1-9. PubMed ID: 22364238
[TBL] [Abstract][Full Text] [Related]
37. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.
Nakamura K; Nakabayashi K; Htet Aung K; Aizawa K; Hori N; Yamauchi J; Hata K; Tanoue A
PLoS One; 2015; 10(3):e0120545. PubMed ID: 25799509
[TBL] [Abstract][Full Text] [Related]
38. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells.
Ben-Kasus T; Ben-Zvi Z; Marquez VE; Kelley JA; Agbaria R
Biochem Pharmacol; 2005 Jul; 70(1):121-33. PubMed ID: 15885659
[TBL] [Abstract][Full Text] [Related]
39. The intravenous and oral pharmacokinetics of afoxolaner used as a monthly chewable antiparasitic for dogs.
Letendre L; Huang R; Kvaternick V; Harriman J; Drag M; Soll M
Vet Parasitol; 2014 Apr; 201(3-4):190-7. PubMed ID: 24685320
[TBL] [Abstract][Full Text] [Related]
40. Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses.
Moore SA; Muñana KR; Papich MG; Nettifee-Osborne J
Am J Vet Res; 2010 Mar; 71(3):337-41. PubMed ID: 20187836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
